ROR1 and B-cell chronic lymphocytic leukemia: In fact, the existence of endogenous anti-ROR1 antibodies that are triggered in CLL patients with clinical responses to an autologous cell vaccine [21] or lenalidomide [41] points to an alternate mechanism of activity.